NCT06890182View on ClinicalTrials.gov

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed

furmonertinib 80mg/d for 12 weeks and carboplatin AUC5 d1 iv / cisplatin 75mg/m2 d1 iv+ pemetrexed 500mg/m2 d1 iv at 21 day cycles for 4 cycles

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER